Compare Abercrombie & Fitch Co. (ANF) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Charles River Laboratories Intl. Inc — how do they compare? Abercrombie & Fitch Co. trades at $113.92 (market cap $5.24B), while Charles River Laboratories Intl. Inc trades at $285.21 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.6× Abercrombie & Fitch Co.'s market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | CRL | |
|---|---|---|
Market Cap | $5.24B | $13.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $282.00 |
52-Week Low | $65.61 | $145.57 |
Enterprise Value | $5.91B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $118.53, up 5.25% today, reflecting strong momentum. The stock exhibits bullish technical signals with support at $114 and resistance at $121. Fundamentally, the company reported robust earnings, with Q1 2026 EPS of $1.47 beating expectations of $1.28, and revenue growth from $4.3B in 2024 to $4.95B in 2025. Profitability metrics are solid, with a net income margin of 11.44% in 2025 and ROE of 39.04%.
Outlook is positive due to consistent earnings beats and strategic campaigns, but risks include market volatility and competitive pressures. Analysts are mixed with a consensus price target of $112.86, below the current price, suggesting potential overvaluation. Institutional interest is growing, with Amundi increasing its stake by 201.2% in Q2 2026.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
